BeOne Medicines AG (NASDAQ: ONC) Stock Competitors & Peer Comparison
See ONC's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ONC and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ONC | $347.48 | -2.40% | 37.1B | 61.18 | $5.68 | N/A |
| VRTX | $505.75 | -2.07% | 128.4B | 26.58 | $19.03 | N/A |
| REGN | $803.48 | -0.31% | 82.8B | 17.61 | $45.63 | +0.45% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $851.29 | -0.66% | 52.9B | 76.83 | $11.08 | N/A |
| RVMDW | $11.10 | +0.00% | 44B | -1.55 | -$7.21 | N/A |
| RVMD | $203.71 | +0.85% | 43.3B | -23.10 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $228.65 | +0.67% | 30.6B | 41.20 | $5.55 | N/A |
| INSM | $123.74 | -2.05% | 26.8B | -27.08 | -$4.57 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
ONC vs VRTX Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, VRTX has a market cap of 128.4B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while VRTX trades at $505.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas VRTX's P/E ratio is 26.58. In terms of profitability, ONC's ROE is +0.14%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, ONC is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
ONC vs REGN Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, REGN has a market cap of 82.8B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while REGN trades at $803.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas REGN's P/E ratio is 17.61. In terms of profitability, ONC's ROE is +0.14%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ONC is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for ONC.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
ONC vs VRNA Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ONC's ROE is +0.14%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ONC is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ONC.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
ONC vs ARGX Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, ARGX has a market cap of 52.9B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while ARGX trades at $851.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas ARGX's P/E ratio is 76.83. In terms of profitability, ONC's ROE is +0.14%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, ONC is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check ARGX's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
ONC vs RVMDW Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, RVMDW has a market cap of 44B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while RVMDW trades at $11.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas RVMDW's P/E ratio is -1.55. In terms of profitability, ONC's ROE is +0.14%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, ONC is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for ONC.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
ONC vs RVMD Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, RVMD has a market cap of 43.3B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while RVMD trades at $203.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas RVMD's P/E ratio is -23.10. In terms of profitability, ONC's ROE is +0.14%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, ONC is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for ONC.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
ONC vs SGEN Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ONC's ROE is +0.14%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ONC is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ONC.Check SGEN's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
ONC vs ALNY Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, ALNY has a market cap of 30.6B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while ALNY trades at $228.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas ALNY's P/E ratio is 41.20. In terms of profitability, ONC's ROE is +0.14%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, ONC is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ALNY's competition here
Insmed Incorporated (NASDAQ: INSM)
ONC vs INSM Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, INSM has a market cap of 26.8B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while INSM trades at $123.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas INSM's P/E ratio is -27.08. In terms of profitability, ONC's ROE is +0.14%, compared to INSM's ROE of -1.11%. Regarding short-term risk, ONC is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for ONC.Check INSM's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
ONC vs ROIV Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, ROIV has a market cap of 26.2B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while ROIV trades at $36.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas ROIV's P/E ratio is -34.44. In terms of profitability, ONC's ROE is +0.14%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, ONC is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for ONC.Check ROIV's competition here
Moderna, Inc. (NASDAQ: MRNA)
ONC vs MRNA Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, MRNA has a market cap of 25.1B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while MRNA trades at $63.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas MRNA's P/E ratio is -7.77. In terms of profitability, ONC's ROE is +0.14%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, ONC is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for ONC.Check MRNA's competition here
Incyte Corporation (NASDAQ: INCY)
ONC vs INCY Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, INCY has a market cap of 24.4B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while INCY trades at $120.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas INCY's P/E ratio is 16.15. In terms of profitability, ONC's ROE is +0.14%, compared to INCY's ROE of +0.30%. Regarding short-term risk, ONC is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for ONC.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
ONC vs BNTX Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, BNTX has a market cap of 23.4B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while BNTX trades at $93.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas BNTX's P/E ratio is -16.84. In terms of profitability, ONC's ROE is +0.14%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, ONC is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
ONC vs UTHR Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, UTHR has a market cap of 21.2B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while UTHR trades at $499.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas UTHR's P/E ratio is 17.88. In terms of profitability, ONC's ROE is +0.14%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, ONC is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for ONC.Check UTHR's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
ONC vs BGNE Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ONC's ROE is +0.14%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, ONC is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ONC.Check BGNE's competition here
Genmab A/S (NASDAQ: GMAB)
ONC vs GMAB Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, GMAB has a market cap of 19.6B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while GMAB trades at $31.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas GMAB's P/E ratio is 24.07. In terms of profitability, ONC's ROE is +0.14%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, ONC is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for ONC.Check GMAB's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
ONC vs DNA-WT Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ONC's ROE is +0.14%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, ONC is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for ONC.Check DNA-WT's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
ONC vs BBIO Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, BBIO has a market cap of 15.6B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while BBIO trades at $79.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas BBIO's P/E ratio is -21.35. In terms of profitability, ONC's ROE is +0.14%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, ONC is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for ONC.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
ONC vs ASND Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, ASND has a market cap of 15.4B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while ASND trades at $248.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas ASND's P/E ratio is -102.69. In terms of profitability, ONC's ROE is +0.14%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ONC is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ASND's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
ONC vs JAZZ Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, JAZZ has a market cap of 15.4B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while JAZZ trades at $244.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas JAZZ's P/E ratio is 9.13. In terms of profitability, ONC's ROE is +0.14%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, ONC is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for ONC.Check JAZZ's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
ONC vs NBIX Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, NBIX has a market cap of 15.4B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while NBIX trades at $152.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas NBIX's P/E ratio is 22.07. In terms of profitability, ONC's ROE is +0.14%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, ONC is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check NBIX's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
ONC vs BMRN Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, BMRN has a market cap of 13B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while BMRN trades at $67.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas BMRN's P/E ratio is 32.38. In terms of profitability, ONC's ROE is +0.14%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, ONC is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for ONC.Check BMRN's competition here
Exelixis, Inc. (NASDAQ: EXEL)
ONC vs EXEL Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, EXEL has a market cap of 12.9B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while EXEL trades at $51.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas EXEL's P/E ratio is 14.64. In terms of profitability, ONC's ROE is +0.14%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, ONC is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for ONC.Check EXEL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
ONC vs KRTX Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ONC's ROE is +0.14%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ONC is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
ONC vs ARWR Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, ARWR has a market cap of 12.2B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while ARWR trades at $86.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas ARWR's P/E ratio is -38.51. In terms of profitability, ONC's ROE is +0.14%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, ONC is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ARWR's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
ONC vs MDGL Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, MDGL has a market cap of 11.7B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while MDGL trades at $507.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas MDGL's P/E ratio is -39.65. In terms of profitability, ONC's ROE is +0.14%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, ONC is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for ONC.Check MDGL's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
ONC vs HALO Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, HALO has a market cap of 11.7B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while HALO trades at $98.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas HALO's P/E ratio is 18.41. In terms of profitability, ONC's ROE is +0.14%, compared to HALO's ROE of +1.81%. Regarding short-term risk, ONC is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for ONC.Check HALO's competition here
Bio-Techne Corporation (NASDAQ: TECH)
ONC vs TECH Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while TECH trades at $72.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas TECH's P/E ratio is 37.32. In terms of profitability, ONC's ROE is +0.14%, compared to TECH's ROE of +0.09%. Regarding short-term risk, ONC is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ONC.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
ONC vs RNAM Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ONC's ROE is +0.14%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ONC is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ONC.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
ONC vs AXSM Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, AXSM has a market cap of 11B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while AXSM trades at $213.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas AXSM's P/E ratio is -55.79. In terms of profitability, ONC's ROE is +0.14%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, ONC is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for ONC.Check AXSM's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
ONC vs SMMT Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, SMMT has a market cap of 10.6B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while SMMT trades at $13.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas SMMT's P/E ratio is -8.34. In terms of profitability, ONC's ROE is +0.14%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ONC is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for ONC.Check SMMT's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
ONC vs PRAX Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, PRAX has a market cap of 10.2B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while PRAX trades at $366.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas PRAX's P/E ratio is -28.37. In terms of profitability, ONC's ROE is +0.14%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, ONC is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check PRAX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
ONC vs PTGX Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, PTGX has a market cap of 10B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while PTGX trades at $155.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas PTGX's P/E ratio is 150.58. In terms of profitability, ONC's ROE is +0.14%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, ONC is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check PTGX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
ONC vs KRYS Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, KRYS has a market cap of 9.8B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while KRYS trades at $332.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas KRYS's P/E ratio is 41.64. In terms of profitability, ONC's ROE is +0.14%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ONC is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for ONC.Check KRYS's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
ONC vs KYMR Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, KYMR has a market cap of 9.7B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while KYMR trades at $117.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas KYMR's P/E ratio is -36.68. In terms of profitability, ONC's ROE is +0.14%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, ONC is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for ONC.Check KYMR's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
ONC vs RXDX Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ONC's ROE is +0.14%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ONC is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check RXDX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
ONC vs IONS Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, IONS has a market cap of 9.5B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while IONS trades at $57.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas IONS's P/E ratio is -33.28. In terms of profitability, ONC's ROE is +0.14%, compared to IONS's ROE of -1.11%. Regarding short-term risk, ONC is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for ONC.Check IONS's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
ONC vs CYTK Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, CYTK has a market cap of 9.1B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while CYTK trades at $74.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas CYTK's P/E ratio is -11.83. In terms of profitability, ONC's ROE is +0.14%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, ONC is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for ONC.Check CYTK's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
ONC vs NUVL Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ONC's ROE is +0.14%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ONC is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ONC.Check NUVL's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
ONC vs SYRE Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, SYRE has a market cap of 9B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while SYRE trades at $103.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas SYRE's P/E ratio is -53.14. In terms of profitability, ONC's ROE is +0.14%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, ONC is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for ONC.Check SYRE's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
ONC vs CRNX Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while CRNX trades at $84.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas CRNX's P/E ratio is -16.81. In terms of profitability, ONC's ROE is +0.14%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ONC is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check CRNX's competition here
Abivax S.A. (NASDAQ: ABVX)
ONC vs ABVX Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, ABVX has a market cap of 8.7B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while ABVX trades at $118.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas ABVX's P/E ratio is -62.36. In terms of profitability, ONC's ROE is +0.14%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ONC is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ABVX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
ONC vs IMGN Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ONC's ROE is +0.14%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ONC is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ONC.Check IMGN's competition here
Immunovant, Inc. (NASDAQ: IMVT)
ONC vs IMVT Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, IMVT has a market cap of 8.6B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while IMVT trades at $41.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas IMVT's P/E ratio is -14.83. In terms of profitability, ONC's ROE is +0.14%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, ONC is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for ONC.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
ONC vs PCVX Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while PCVX trades at $58.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas PCVX's P/E ratio is -7.61. In terms of profitability, ONC's ROE is +0.14%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, ONC is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check PCVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
ONC vs BPMC Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ONC's ROE is +0.14%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ONC is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ONC.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
ONC vs APGE Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while APGE trades at $134.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas APGE's P/E ratio is -31.07. In terms of profitability, ONC's ROE is +0.14%, compared to APGE's ROE of -0.30%. Regarding short-term risk, ONC is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ONC.Check APGE's competition here
Alkermes plc (NASDAQ: ALKS)
ONC vs ALKS Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, ALKS has a market cap of 8.2B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while ALKS trades at $49.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas ALKS's P/E ratio is 51.64. In terms of profitability, ONC's ROE is +0.14%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, ONC is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ALKS's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
ONC vs CERE Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas CERE's P/E ratio is -16.47. In terms of profitability, ONC's ROE is +0.14%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ONC is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ONC.Check CERE's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
ONC vs IBRX Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, IBRX has a market cap of 7.9B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while IBRX trades at $7.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas IBRX's P/E ratio is -7.80. In terms of profitability, ONC's ROE is +0.14%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, ONC is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check IBRX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
ONC vs RYTM Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, RYTM has a market cap of 7.9B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while RYTM trades at $115.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas RYTM's P/E ratio is -37.13. In terms of profitability, ONC's ROE is +0.14%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, ONC is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for ONC.Check RYTM's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
ONC vs TGTX Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, TGTX has a market cap of 7.5B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while TGTX trades at $48.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas TGTX's P/E ratio is 17.66. In terms of profitability, ONC's ROE is +0.14%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, ONC is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check TGTX's competition here
Metsera, Inc. (NASDAQ: MTSR)
ONC vs MTSR Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ONC's ROE is +0.14%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ONC is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ONC.Check MTSR's competition here
Merus N.V. (NASDAQ: MRUS)
ONC vs MRUS Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ONC's ROE is +0.14%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ONC is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ONC.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
ONC vs ACLX Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ONC's ROE is +0.14%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ONC is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check ACLX's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
ONC vs ORKA Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, ORKA has a market cap of 6.7B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while ORKA trades at $111.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas ORKA's P/E ratio is -57.24. In terms of profitability, ONC's ROE is +0.14%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, ONC is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ORKA's competition here
CG Oncology Inc. (NASDAQ: CGON)
ONC vs CGON Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while CGON trades at $75.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas CGON's P/E ratio is -27.89. In terms of profitability, ONC's ROE is +0.14%, compared to CGON's ROE of -0.25%. Regarding short-term risk, ONC is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for ONC.Check CGON's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
ONC vs RETA Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas RETA's P/E ratio is -66.29. In terms of profitability, ONC's ROE is +0.14%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ONC is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ONC.Check RETA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
ONC vs BLTE Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, BLTE has a market cap of 6.5B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while BLTE trades at $162.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas BLTE's P/E ratio is -87.06. In terms of profitability, ONC's ROE is +0.14%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, ONC is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for ONC.Check BLTE's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
ONC vs DNTH Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, DNTH has a market cap of 6.5B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while DNTH trades at $115.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas DNTH's P/E ratio is -27.94. In terms of profitability, ONC's ROE is +0.14%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, ONC is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for ONC.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
ONC vs COGT Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, COGT has a market cap of 6.5B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while COGT trades at $37.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas COGT's P/E ratio is -17.98. In terms of profitability, ONC's ROE is +0.14%, compared to COGT's ROE of -0.73%. Regarding short-term risk, ONC is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for ONC.Check COGT's competition here
Erasca, Inc. (NASDAQ: ERAS)
ONC vs ERAS Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, ERAS has a market cap of 6.4B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while ERAS trades at $18.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas ERAS's P/E ratio is -19.76. In terms of profitability, ONC's ROE is +0.14%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, ONC is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ERAS's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
ONC vs SRRK Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, SRRK has a market cap of 6.3B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while SRRK trades at $52.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas SRRK's P/E ratio is -15.22. In terms of profitability, ONC's ROE is +0.14%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, ONC is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for ONC.Check SRRK's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
ONC vs CNTA Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ONC's ROE is +0.14%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ONC is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ONC.Check CNTA's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
ONC vs CAI Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, CAI has a market cap of 6.2B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while CAI trades at $21.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas CAI's P/E ratio is 61.25. In terms of profitability, ONC's ROE is +0.14%, compared to CAI's ROE of +0.19%. Regarding short-term risk, ONC is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for ONC.Check CAI's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
ONC vs MIRM Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while MIRM trades at $100.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas MIRM's P/E ratio is -6.92. In terms of profitability, ONC's ROE is +0.14%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, ONC is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for ONC.Check MIRM's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
ONC vs XENE Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, XENE has a market cap of 6B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while XENE trades at $62.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas XENE's P/E ratio is -13.27. In terms of profitability, ONC's ROE is +0.14%, compared to XENE's ROE of -0.44%. Regarding short-term risk, ONC is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for ONC.Check XENE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
ONC vs PTCT Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, PTCT has a market cap of 6B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while PTCT trades at $71.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas PTCT's P/E ratio is -30.77. In terms of profitability, ONC's ROE is +0.14%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, ONC is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for ONC.Check PTCT's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
ONC vs LGND Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, LGND has a market cap of 5.9B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while LGND trades at $294.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas LGND's P/E ratio is 32.34. In terms of profitability, ONC's ROE is +0.14%, compared to LGND's ROE of +0.20%. Regarding short-term risk, ONC is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for ONC.Check LGND's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
ONC vs DFTX Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, DFTX has a market cap of 5.8B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while DFTX trades at $42.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas DFTX's P/E ratio is N/A. In terms of profitability, ONC's ROE is +0.14%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, ONC is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check DFTX's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
ONC vs TVTX Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, TVTX has a market cap of 5.8B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while TVTX trades at $62.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas TVTX's P/E ratio is -138.09. In terms of profitability, ONC's ROE is +0.14%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, ONC is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check TVTX's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
ONC vs CDTX Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ONC's ROE is +0.14%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ONC is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
ONC vs ABCM Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ONC's ROE is +0.14%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ONC is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ONC.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
ONC vs ISEE Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ONC's ROE is +0.14%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ONC is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ONC.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
ONC vs APLS Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas APLS's P/E ratio is 38.35. In terms of profitability, ONC's ROE is +0.14%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ONC is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ONC.Check APLS's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
ONC vs CRSP Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while CRSP trades at $53.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas CRSP's P/E ratio is -11.25. In terms of profitability, ONC's ROE is +0.14%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, ONC is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for ONC.Check CRSP's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
ONC vs DYN Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, DYN has a market cap of 4.8B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while DYN trades at $25.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas DYN's P/E ratio is -8.06. In terms of profitability, ONC's ROE is +0.14%, compared to DYN's ROE of -0.64%. Regarding short-term risk, ONC is more volatile compared to DYN. This indicates higher risk in terms of short-term price fluctuations for ONC.Check DYN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
ONC vs ACAD Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, ACAD has a market cap of 4.8B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while ACAD trades at $28.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas ACAD's P/E ratio is 13.71. In terms of profitability, ONC's ROE is +0.14%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, ONC is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for ONC.Check ACAD's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
ONC vs TERN Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas TERN's P/E ratio is -51.41. In terms of profitability, ONC's ROE is +0.14%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ONC is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ONC.Check TERN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
ONC vs EWTX Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while EWTX trades at $44.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas EWTX's P/E ratio is -23.88. In terms of profitability, ONC's ROE is +0.14%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, ONC is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check EWTX's competition here
Veradermics, Incorporated (NYSE: MANE)
ONC vs MANE Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, MANE has a market cap of 4.7B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while MANE trades at $112.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas MANE's P/E ratio is -35.90. In terms of profitability, ONC's ROE is +0.14%, compared to MANE's ROE of -0.29%. Regarding short-term risk, ONC is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for ONC.Check MANE's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
ONC vs FOLD Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ONC's ROE is +0.14%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ONC is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ONC.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
ONC vs AKRO Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ONC's ROE is +0.14%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ONC is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ONC.Check AKRO's competition here
Celcuity Inc. (NASDAQ: CELC)
ONC vs CELC Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, CELC has a market cap of 4.5B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while CELC trades at $92.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas CELC's P/E ratio is -23.59. In terms of profitability, ONC's ROE is +0.14%, compared to CELC's ROE of -3.51%. Regarding short-term risk, ONC is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for ONC.Check CELC's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
ONC vs ALPN Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ONC's ROE is +0.14%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ONC is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ONC.Check ALPN's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
ONC vs RLAY Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, RLAY has a market cap of 4.4B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while RLAY trades at $19.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas RLAY's P/E ratio is -12.65. In terms of profitability, ONC's ROE is +0.14%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, ONC is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for ONC.Check RLAY's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
ONC vs PBLS Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, PBLS has a market cap of 4.3B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while PBLS trades at $37.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas PBLS's P/E ratio is -42.12. In terms of profitability, ONC's ROE is +0.14%, compared to PBLS's ROE of N/A. Regarding short-term risk, ONC is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for ONC.Check PBLS's competition here
Opthea Limited (NASDAQ: OPT)
ONC vs OPT Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas OPT's P/E ratio is -1.52. In terms of profitability, ONC's ROE is +0.14%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ONC is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ONC.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
ONC vs PRTC Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ONC's ROE is +0.14%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ONC is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for ONC.Check PRTC's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
ONC vs ELVN Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, ELVN has a market cap of 4.2B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while ELVN trades at $58.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas ELVN's P/E ratio is -35.22. In terms of profitability, ONC's ROE is +0.14%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, ONC is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ELVN's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
ONC vs TNGX Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, TNGX has a market cap of 4.2B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while TNGX trades at $25.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas TNGX's P/E ratio is -30.84. In terms of profitability, ONC's ROE is +0.14%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, ONC is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check TNGX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
ONC vs MRTX Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ONC's ROE is +0.14%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ONC is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check MRTX's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
ONC vs TLX Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, TLX has a market cap of 4B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while TLX trades at $11.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas TLX's P/E ratio is -642.39. In terms of profitability, ONC's ROE is +0.14%, compared to TLX's ROE of -0.02%. Regarding short-term risk, ONC is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check TLX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
ONC vs ADPT Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, ADPT has a market cap of 4B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while ADPT trades at $24.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas ADPT's P/E ratio is -60.34. In terms of profitability, ONC's ROE is +0.14%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, ONC is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ADPT's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
ONC vs DNLI Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, DNLI has a market cap of 3.9B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while DNLI trades at $24.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas DNLI's P/E ratio is -8.47. In terms of profitability, ONC's ROE is +0.14%, compared to DNLI's ROE of -0.55%. Regarding short-term risk, ONC is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for ONC.Check DNLI's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
ONC vs VKTX Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, VKTX has a market cap of 3.9B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while VKTX trades at $33.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas VKTX's P/E ratio is -8.02. In terms of profitability, ONC's ROE is +0.14%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, ONC is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check VKTX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
ONC vs CPRX Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas CPRX's P/E ratio is 12.30. In terms of profitability, ONC's ROE is +0.14%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ONC is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check CPRX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
ONC vs LEGN Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, LEGN has a market cap of 3.8B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while LEGN trades at $20.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas LEGN's P/E ratio is -29.96. In terms of profitability, ONC's ROE is +0.14%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, ONC is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for ONC.Check LEGN's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
ONC vs RYZB Comparison August 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 37.1B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ONC is priced at $347.48 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 61.18, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ONC's ROE is +0.14%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ONC is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ONC.Check RYZB's competition here